TOT BIOPHARM Co Ltd
http://www.totbiopharm.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TOT BIOPHARM Co Ltd
Legend Buyout Report Boosts, Validates China Biotech
A reported buyout bid for Legend Biotech has delivered a much needed shot of confidence to the Chinese biotech sector, despite not being confirmed. Amid a shifting environment, Hengrui also sees globalization as essential to its future.
M&A Activity During Q2 Declined In Volume And Valuation
Following a pair of $10bn+ deals in Q4 2023 and a $16.5bn takeout in Q1, the second quarter saw no acquisition priced as high as $5bn, Evaluate notes. Aggregate deal volume and values dropped from Q1.
The Scrip Awards Podcast, Episode 1: Genmab: The Ongoing Evolution Of Europe’s Antibody Powerhouse
A new podcast series marking 20 years of the Scrip Awards and their recognition of biopharma sector innovation.
China Biotech Podcast: AACR, BIOSECURE European Perspectives
Guest Andrew McConaghie from Scrip's UK team joins Brian Yang and Dexter Yan to discuss AACR highlights from Chinese biotechs, European perspectives on the proposed US BIOSECURE Act, two recent acquisitions and Boehringer Ingelheim's recent quarterly results.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice